Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/11/2018
SIETES contiene 92577 citas

 
 
 1 a 20 de 3674 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Nguyen TTH, Roussin A, Rousseau A, Montastruc J-L, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological–pharmacodynamic study in VigiBase®. Drug Saf 2018;41:noviembre. [Ref.ID 102840]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Samper E. Así influyen las farmacéuticas sobre los médicos . eldiario.es 2018:18 de octubre. [Ref.ID 102834]
3. Cita con resumen
Anónimo. FDA warns SGLT2 inhibitors can cause flesh-eating genitali infection. DIA Daily 2018:1. [Ref.ID 102830]
4.Enlace a cita original Cita con resumen
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 2018:13 de agosto. [Ref.ID 102824]
5.Enlace a cita original Cita con resumen
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]
6.Enlace a cita original Cita con resumen
Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Sénat M-V, Affres H, Letourneau A, Coustols-Valat M, Cazaubiel M, Legardeur H, Jacquier JF, Bourcigaux N, Simon E, Rod A, Héron I, Castera V, Sentilhes L, Bretelle F, Rolland C, Morin M, Deruelle P, De Carne C, Maillot F, Beucher G, Verspyck E, Desbriere R, Laboureau S, Mitanchez D, Bouyer J, for the Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes. A randomized clinical trial. JAMA 2018;319:1 de junio. [Ref.ID 102766]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Coustan DR, Barbour L. Insulin vs glyburide for gestational diabetes. JAMA 2018;319:1 de junio. [Ref.ID 102765]
9.Enlace a cita original Cita con resumen
Rothwell PPM, Cook PNR, Gaziano PJM, Price JF, Belch PJFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018:12 de julio. [Ref.ID 102745]
10.Enlace a cita original Cita con resumen
Palmer SC, Strippoli GFM. Metformin as first-line treatment for type 2 diabetes . Lancet 2018;392:14 de julio. [Ref.ID 102743]
11.Enlace a cita original Cita con resumen
Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018;391:30 de junio. [Ref.ID 102741]
12.Enlace a cita original Cita con resumen
Ovalle F, Grimes T, Xu G, Patel AJ, Grayson TB, Thielen LA, Li P, Shalev A. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med 2018:9 de julio. [Ref.ID 102718]
13. Cita con resumen
Anónimo. Increasing cost of insulin sparks concern. DIA Daily 2018:1. [Ref.ID 102700]
14. Cita con resumen
Given JE, Loane M, Garne E, Addor M-C, Bakker M, Bertaut-Nativel B, Gatt M, Klungsoyr K, Lelong N, Morgan M, Neville AJ, Pierini A, Rißmann A, Dolk H. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ 2018;361:k2477. [Ref.ID 102696]
16.Enlace a cita original Cita con resumen
Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry 2018:7 de mayo. [Ref.ID 102604]
17.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:21 de marzo. [Ref.ID 102562]
18.Enlace a cita original Cita con resumen
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]
20. Cita con resumen
Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking ß-blockers. Mayo Clin Proc 2017;93:409-18. [Ref.ID 102505]
Seleccionar todas
 
 1 a 20 de 3674 siguiente >>